[go: up one dir, main page]

NO940524L - - Google Patents

Info

Publication number
NO940524L
NO940524L NO940524A NO940524A NO940524L NO 940524 L NO940524 L NO 940524L NO 940524 A NO940524 A NO 940524A NO 940524 A NO940524 A NO 940524A NO 940524 L NO940524 L NO 940524L
Authority
NO
Norway
Prior art keywords
condensed
bases
inorganic
compounds
processes
Prior art date
Application number
NO940524A
Other languages
Norwegian (no)
Other versions
NO940524D0 (en
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of NO940524D0 publication Critical patent/NO940524D0/en
Publication of NO940524L publication Critical patent/NO940524L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår kondenserte 5-leddede heterocykler med den generelle formel A-B , (D hvor A, B, Yj og Y2 og Xx til X4 er som definert i krav l, deres tautomerer, deres stereoisomerer, innbefattet deres blandinger, og deres salter, spesielt deres fysiologisk akseptable salter, med uorganiske eller organiske syrer eller baser, som oppviser verdifulle farmakologiske egenskaper, fortrinnsvis aggregasjonshemmende virkninger, legemidler som inneholder disse forbindelser samt fremgangsmåter for deres fremstilling.The invention relates to condensed 5-membered heterocycles of the general formula AB, (D wherein A, B, Yj and Y2 and Xx to X4 are as defined in claim 1, physiologically acceptable salts, with inorganic or organic acids or bases, which exhibit valuable pharmacological properties, preferably aggregation inhibitory effects, drugs containing these compounds, and processes for their preparation.

NO940524A 1993-02-16 1994-02-15 Condensed 5-membered heterocycles, process for their preparation, and drugs containing these compounds NO940524D0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4304650A DE4304650A1 (en) 1993-02-16 1993-02-16 Condensed 5-membered heterocycles, processes for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
NO940524D0 NO940524D0 (en) 1994-02-15
NO940524L true NO940524L (en) 1994-08-17

Family

ID=6480585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940524A NO940524D0 (en) 1993-02-16 1994-02-15 Condensed 5-membered heterocycles, process for their preparation, and drugs containing these compounds

Country Status (10)

Country Link
EP (1) EP0611660A3 (en)
JP (1) JPH072839A (en)
AU (1) AU5513094A (en)
CA (1) CA2115737A1 (en)
DE (1) DE4304650A1 (en)
FI (1) FI940697A7 (en)
IL (1) IL108648A0 (en)
NO (1) NO940524D0 (en)
NZ (1) NZ250879A (en)
ZA (1) ZA941021B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751647B1 (en) * 1996-07-25 1998-09-11 Synthelabo BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATIONS AND THEIR THERAPEUTIC APPLICATIONS
TR200001079T2 (en) 1997-10-20 2000-07-21 F.Hoffmann-La Roche Ag Bicyclic kinase inhibitors.
EA005974B1 (en) 2001-02-23 2005-08-25 Мерк Энд Ко., Инк. N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
EA200400595A1 (en) 2001-11-09 2004-10-28 Бёрингер Ингельхайм Фармасьютиклз, Инк. BENZIMIDAZOLY, USED AS PROTEKINKINASE INHIBITORS
WO2004014905A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
ES2524803T3 (en) 2002-12-19 2014-12-12 The Scripps Research Institute Compositions and methods to stabilize transthyretin and inhibit the abnormal folding of transthyretin
EP1479676A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Benzimidazole-derivatives as factor xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
US20050261365A1 (en) 2004-05-20 2005-11-24 The Scripps Research Institute Transthyretin stabilization
WO2009086077A2 (en) * 2007-12-21 2009-07-09 Endacea, Inc. A1 adenosine receptor antagonists
KR20140054231A (en) 2011-09-16 2014-05-08 화이자 인코포레이티드 Solid forms of a transthyretin dissociation inhibitor
EP2956450B1 (en) 2013-02-14 2018-07-25 Technische Universität München Hydroxyindalpine derivatives and their medical use
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
DK2970303T6 (en) * 2013-03-15 2018-10-08 Hydra Biosciences Inc SUBSTITUTED XANTHINES AND PROCEDURES FOR USING IT
TN2016000253A1 (en) 2013-12-19 2017-10-06 Novartis Ag [1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis.
JP6403865B2 (en) * 2014-07-03 2018-10-10 シャンハイ インスティテュート オブ ファーマシューティカル インダストリー Method for producing dabigatran etexilate intermediate and intermediate compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2208367B (en) 1987-07-09 1991-07-03 Alcatel Business Systems Franking machine
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DE4124942A1 (en) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENTS CONTAINING SUCH COMPOUNDS
DE4129603A1 (en) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
DE4214245A1 (en) * 1992-04-30 1993-11-04 Thomae Gmbh Dr K TRITIUM-MARKED FIBRINOGEN RECEPTOR ANTAGONISTS, THEIR USE AND METHOD FOR THEIR PRODUCTION
ATE140225T1 (en) * 1992-04-28 1996-07-15 Thomae Gmbh Dr K TRITIUM LABELED FIBRINOGEN RECEPTOR ANTAGONISTS, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF

Also Published As

Publication number Publication date
EP0611660A3 (en) 1994-09-14
FI940697A7 (en) 1994-08-17
NZ250879A (en) 1995-09-26
DE4304650A1 (en) 1994-08-18
ZA941021B (en) 1995-08-15
FI940697A0 (en) 1994-02-15
CA2115737A1 (en) 1994-08-17
NO940524D0 (en) 1994-02-15
JPH072839A (en) 1995-01-06
AU5513094A (en) 1994-08-18
IL108648A0 (en) 1994-05-30
EP0611660A2 (en) 1994-08-24

Similar Documents

Publication Publication Date Title
NO940524L (en)
NO922940L (en) FIVE-JOINT HETEROCYCLIC COMPOUNDS, PROCEDURES FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM
NO923235L (en) CYCLIC IMINO DERIVATIVES, AND PROCEDURES FOR PREPARING SUCH THINGS.
NO923466L (en) Heterocyclic Compounds with 5 Sections, PROCEDURE PREPARATION, AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS
NO920957L (en) CYCLE URINARY DERIVATIVES AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS
NO933248L (en) Cyclic urea derivatives, drugs containing these compounds, and process for their preparation
NO934501L (en) Carboxylic acid derivatives, drugs containing these compounds, and process for their preparation
NO940261L (en) 5-membered heterocycles, process for the preparation thereof and drugs containing these compounds
NO972881L (en) Piperazine derivatives, drugs containing them, their use and methods for their preparation
NO941677D0 (en) Tetrazole derivatives of bile acids, methods of preparation and their use as a drug
NO931526D0 (en) CYCLIC IMINO DERIVATIVES, PROCEDURES FOR THEIR PREPARATION, AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
CA2054850A1 (en) Cyclic imino derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
NO941680D0 (en) Monomeric bile acid derivatives, processes for their preparation and their use as a drug
NO932120L (en) Biphenyl derivatives, drugs containing them, and methods for their preparation
RU95101048A (en) Prolineamide derivatives and pharmcomposition based thereon
NO941678D0 (en) nor- bile acid derivatives, process for the preparation and use of them as a drug
MX9803954A (en) Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them.
DK0726899T3 (en) New pyrazinecarboxamide derivatives, their preparation and their use in pharmaceuticals
NO931527L (en) CYCLIC IMINO DERIVATIVES, MEDICINAL PREPARATIONS CONTAINING THESE, AND PROCEDURE FOR THEIR PREPARATION
NO924921L (en) POLYASPARTAMIDE DERIVATIVES AS A BILIC ACID ADDRESSOR, POLYASPARTAMIDE DERIVATIVE LOADED WITH BALLY ACIDS AND PROCEDURES FOR THE PRODUCTION OF THESE, AND THEIR USE AS A MEDICINE
ES2140396T3 (en) COMPOUND OF TIENODIAZEPINE AND ITS USE.
NO880473L (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTED 3,4-DIHYDRO-2H-BENZOPYRANES AND THEIR USE AS A MEDICINE.
KR890009389A (en) How to suppress the virus
NO301826B1 (en) Heterotricyclic substituted phenylcyclohexanecarboxylic acid derivatives, drugs containing them and their use in the manufacture of drugs
NO883986D0 (en) PROCEDURE FOR THE PREPARATION OF N- (SUBSTITUTED ALKYLIDE) -1,2,3,4-TETRAHYDRO-9 ACRIDINAMINES AND USE THEREOF AS MEDICINES.